The molecules: Mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension

Journal of Clinical Gastroenterology

Volumn 41, Issue SUPPL. 3, 2007, Pages

  Iwakiri, Yasuko ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

eNOS; Liver cirrhosis; Nitric oxide; Portal hypertension; Vasodilatation

Indexed keywords

ADRENOMEDULLIN; CARBON MONOXIDE; ENDOCANNABINOID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; HYDROGEN SULFIDE; ISOENZYME; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTACYCLIN; PROTEIN KINASE (CALCIUM,CALMODULIN); SEMAXANIB; SULFUR; TETRAHYDROBIOPTERIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASODILATOR AGENT;

CELLULAR DISTRIBUTION; CONFERENCE PAPER; HEMODYNAMICS; HUMAN; HYPOVOLEMIA; LIVER CIRRHOSIS; MOLECULAR DYNAMICS; NITROSYLATION; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SODIUM RETENTION; SPLANCHNIC BLOOD FLOW; SYSTEMIC CIRCULATION; UPREGULATION; VASODILATATION;

ADRENOMEDULLIN; ANIMALS; ARTERIES; BIOLOGICAL FACTORS; CARBON MONOXIDE; COENZYMES; ENDOCANNABINOIDS; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; HUMANS; HYDROGEN SULFIDE; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PORTAL PRESSURE; SPLANCHNIC CIRCULATION; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASODILATION; VASODILATOR AGENTS;

EID: 35848962696     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181468b4c     Document Type: Conference Paper

References (108)

1. Groszmann RJ, Loureiro-Silva M, Tsai MH. The Biology of Portal Hypertension. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.
2. Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol. 2007;46:927-934.
3. Groszmann RJ, Abraldes JG. Portal hypertension: from bedside to bench. J Clin Gastroenterol. 2005;39:S125-S130.
4. Sieber CC, Groszmann RJ. Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats. Gastroenterology. 1992;103:235-239.
5. Sieber CC, Lopez-Talavera JC, Groszmann RJ. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. Gastroenterology. 1993;104:1750-1754.
6. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006;43:S121-S131.
7. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology. 2002;35:478-491.
8. Battaglia S, Angus P, Chin-Dusting JP. Role of the endothelium on vasoactive agents in patients with liver cirrhosis. J Gastroenterol Hepatol. 2006;21:1189-1193.
9. Morales-Ruiz M, Jimenez W, Perez-Sala D, et al. Increased nitric oxide synthase expression in arterial vessels of cirrhotic rats with ascites. Hepatology. 1996;24:1481-1486.
10. Wiest R, Shah V, Sessa WC, et al. NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol. 1999;276:G1043-G1051.
11. Martin PY, Xu DL, Niederberger M, et al. Upregulation of endothelial constitutive NOS: a major role in the increased NO production in cirrhotic rats. Am J Physiol. 1996;270:F494-F499.
12. Cahill PA, Redmond EM, Hodges R, et al. Increased endothelial nitric oxide synthase activity in the hyperemic vessels of portal hypertensive rats. J Hepatol. 1996;25:370-378.
13. Hori N, Wiest R, Groszmann RJ. Enhanced release of nitric oxide in response to changes in flow and shear stress in the superior mesenteric arteries of portal hypertensive rats. Hepatology. 1998;28:1467-1473.
14. Ignarro LJ, Byrns RE, Wood KS. Endothelium-dependent modulation of cGMP levels and intrinsic smooth muscle tone in isolated bovine intrapulmonary artery and vein. Circ Res. 1987;60:82-92.
15. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-376.
16. Bredt DS, Hwang PM, Snyder SH. Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature. 1990;347:768-770.
17. Bredt DS, Snyder SH. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA. 1990;87:682-685.
18. Xie QW, Cho HJ, Calaycay J, et al. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science. 1992;256:225-228.
19. Tsai MH, Iwakiri Y, Cadelina G, et al. Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats. Gastroenterology. 2003;125:1452-1461.
20. Niederberger M, Gines P, Martin PY, et al. Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats. Hepatology. 1996;24:947-951.
21. Jurzik L, Froh M, Straub RH, et al. Up-regulation of nNOS and associated increase in nitrergic vasodilation in superior mesenteric arteries in pre-hepatic portal hypertension. J Hepatol. 2005;43:258-265.
22. Kwon S, Iwakiri Y, Cadelina G, et al. Neuronal nitric oxide synthase plays a role in the vasodilation observed in the splanchnic circulation in chronic portal hypertensive rats. Hepatology. 2004;40:184A.
23. Xu L, Carter EP, Ohara M, et al. Neuronal nitric oxide synthase and systemic vasodilation in rats with cirrhosis. Am J Physiol Renal Physiol. 2000;279:F1110-F1115.
24. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol. 1997;15:323-350.
25. Cahill PA, Foster C, Redmond EM, et al. Enhanced nitric oxide synthase activity in portal hypertensive rabbits. Hepatology. 1995;22:598-606.
26. Wiest R, Das S, Cadelina G, et al. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest. 1999;104:1223-1233.
27. Tazi KA, Moreau R, Herve P, et al. Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: role of Akt signaling. Gastroenterology. 2005;129:303-314.
28. Moreau R, Barriere E, Tazi KA, et al. Terlipressin inhibits in vivo aortic iNOS expression induced by lipopolysaccharide in rats with biliary cirrhosis. Hepatology. 2002;36:1070-1078.
29. Sessa WC. eNOS at a glance. J Cell Sci. 2004;117:2427-2429.
30. Erwin PA, Lin AJ, Golan DE, et al. Receptor-regulated dynamic S-nitrosylation of endothelial nitric-oxide synthase in vascular endothelial cells. J Biol Chem. 2005;280:19888-19894.
31. Erwin PA, Mitchell DA, Sartoretto J, et al. Subcellular targeting and differential S-nitrosylation of endothelial nitric-oxide synthase. J Biol Chem. 2006;281:151-157.
32. Wiest R, Cadelina G, Milstien S, et al. Bacterial translocation up-regulates GTP-cyclohydrolase I in mesenteric vasculature of cirrhotic rats. Hepatology. 2003;38:1508-1515.
33. Shah V, Wiest R, Garcia-Cardena G, et al. Hsp90 regulation of endothelial nitric oxide synthase contributes to vascular control in portal hypertension. Am J Physiol. 1999;277:G463-G468.
34. Iwakiri Y, Tsai MH, McCabe TJ, et al. Phosphorylation of eNOS initiates excessive NO production in early phases of portal hypertension. Am J Physiol Heart Circ Physiol. 2002;282:H2084-H2090.
35. Dimmeler S, Fleming I, Fisslthaler B, et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399:601-605.
36. Fulton D, Gratton JP, McCabe TJ, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999;399:597-601.
37. Michell BJ, Griffiths JE, Mitchelhill KI, et al. The Akt kinase signals directly to endothelial nitric oxide synthase. Curr Biol. 1999;9:845-848.
38. Gallis B, Corthals GL, Goodlett DR, et al. Identification of flow-dependent endothelial nitric-oxide synthase phosphorylation sites by mass spectrometry and regulation of phosphorylation and nitric oxide production by the phosphatidylinositol 3-kinase inhibitor LY294002. J Biol Chem. 1999;274:30101-30108.
39. Abraldes J, Iwakiri Y, Loureiro-Silva M, et al. Vascular endothelial growth factor (VEGF) up-regulates endothelial nitric oxide synthase (eNOS) in the intestinal microcirculatory bed leading to the hyperdynamic circulatory syndrome in mild portal hypertension. Gastroenterology. 2005;128:A-687.
40. Fernandez M, Mejias M, Angermayr B, et al. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol. 2005;43:98-103.
41. Abraldes JG, Iwakiri Y, Loureiro-Silva M, et al. Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. Am J Physiol Gastrointest Liver Physiol. 2006;290:G980-G987.
42. Rudge JS, Thurston G, Davis S, et al. VEGF trap as a novel antiangiogenic treatment currently in clinical trials for cancer and eye diseases, and VelociGene-based discovery of the next generation of angiogenesis targets. Cold Spring Harb Symp Quant Biol. 2005;70:411-418.
43. Garcia-Cardena G, Oh P, Liu J, et al. Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling. Proc Natl Acad Sci USA. 1996;93:6448-6453.
44. Liu J, Garcia-Cardena G, Sessa WC. Palmitoylation of endothelial nitric oxide synthase is necessary for optimal stimulated release of nitric oxide: implications for caveolae localization. Biochemistry. 1996;35:13277-13281.
45. Sowa G, Liu J, Papapetropoulos A, et al. Trafficking of endothelial nitric-oxide synthase in living cells. Quantitative evidence supporting the role of palmitoylation as a kinetic trapping mechanism limiting membrane diffusion. J Biol Chem. 1999;274:22524-22531.
46. Fulton D, Babbitt R, Zoellner S, et al. Targeting of endothelial nitric-oxide synthase to the cytoplasmic face of the Golgi complex or plasma membrane regulates Akt- versus calcium-dependent mechanisms for nitric oxide release. J Biol Chem. 2004;279:30349-30357.
47. Hess DT, Matsumoto A, Kim SO, et al. Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol. 2005;6:150-166.
48. Chen YC, Gines P, Yang J, et al. Increased vascular heme oxygenase-1 expression contributes to arterial vasodilation in experimental cirrhosis in rats. Hepatology. 2004;39:1075-1087.
49. Fernandez M, Bonkovsky HL. Increased heme oxygenase-1 gene expression in liver cells and splanchnic organs from portal hypertensive rats. Hepatology. 1999;29:1672-1679.
50. Fernandez AZ, Lopez F, Tablante A, et al. Intravascular hemolysis increases atherogenicity of diet-induced hypercholesterolemia in rabbits in spite of heme oxygenase-1 gene and protein induction. Atherosclerosis. 2001;158:103-111.
51. De las Heras D, Fernandez J, Gines P, et al. Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis. Hepatology. 2003;38:452-459.
52. Angermayr B, Mejias M, Gracia-Sancho J, et al. Heme oxygenase attenuates oxidative stress and inflammation, and increases VEGF expression in portal hypertensive rats. J Hepatol. 2006;44:1033-1039.
53. Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol. 1997;37:517-554.
54. Naik JS, Walker BR. Heme oxygenase-mediated vasodilation involves vascular smooth muscle cell hyperpolarization. Am J Physiol Heart Circ Physiol. 2003;285:H220-H228.
55. Ishizuka D, Shirai Y, Hatakeyama K. Duodenal obstruction caused by gallstone impaction into an intraluminal duodenal diverticulum. Am J Gastroenterol. 1997;92:182-183.
56. Zakhary R, Gaine SP, Dinerman JL, et al. Heme oxygenase 2: endothelial and neuronal localization and role in endothelium-dependent relaxation. Proc Natl Acad Sci USA. 1996;93:795-798.
57. Cruse JM, Lewis RE Jr. Cellular and cytokine immunotherapy of cancer. Prog Exp Tumor Res. 1988;32:1-16.
58. Claesson HE, Lindgren JA, Hammarstrom S. Elevation of adenosine 3′,5′-monophosphate levels in 3T3 fibroblasts by arachidonic acid: evidence for mediation by prostaglandin I2. FEBS Lett. 1977;81:415-418.
59. Ohta M, Kishihara F, Hashizume M, et al. Increased prostacyclin content in gastric mucosa of cirrhotic patients with portal hypertensive gastropathy. Prostaglandins Leukot Essent Fatty Acids. 1995;53:41-45.
60. Sitzmann JV, Campbell K, Wu Y, et al. Prostacyclin production in acute, chronic, and long-term experimental portal hypertension. Surgery. 1994;115:290-294.
61. Munoz J, Albillos A, Perez-Paramo M, et al. Factors mediating the hemodynamic effects of tumor necrosis factor-alpha in portal hypertensive rats. Am J Physiol. 1999;276:G687-G693.
62. Wagner JA, Varga K, Ellis EF, et al. Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature. 1997;390:518-521.
63. Batkai S, Jarai Z, Wagner JA, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med. 2001;7:827-832.
64. Ros J, Claria J, To-Figueras J, et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology. 2002;122:85-93.
65. Domenicali M, Ros J, Fernandez-Varo G, et al. Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors. Gut. 2005;54:522-527.
66. Deutsch DG, Goligorsky MS, Schmid PC, et al. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest. 1997;100:1538-1546.
67. Bilfinger TV, Salzet M, Fimiani C, et al. Pharmacological evidence for anandamide amidase in human cardiac and vascular tissues. Int J Cardiol. 1998;64(suppl 1):S15-S22.
68. Hosoki R, Matsuki N, Kimura H. The possible role of hydrogen sulfide as an endogenous smooth muscle relaxant in synergy with nitric oxide. Biochem Biophys Res Commun. 1997;237:527-531.
69. Zhao W, Wang R. H(2)S-induced vasorelaxation and underlying cellular and molecular mechanisms. Am J Physiol Heart Circ Physiol. 2002;283:H474-H480.
70. Cheng Y, Ndisang JF, Tang G, et al. Hydrogen sulfide-induced relaxation of resistance mesenteric artery beds of rats. Am J Physiol Heart Circ Physiol. 2004;287:H2316-H2323.
71. Zhao W, Zhang J, Lu Y, et al. The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. Embo J. 2001;20:6008-6016.
72. Stipanuk MH, Beck PW. Characterization of the enzymic capacity for cysteine desulphhydration in liver and kidney of the rat. Biochem J. 1982;206:267-277.
73. Fiorucci S, Antonelli E, Mencarelli A, et al. The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis. Hepatology. 2005;42:539-548.
74. Hutcheson IR, Chaytor AT, Evans WH, et al. Nitric oxide-independent relaxations to acetylcholine and A23187 involve different routes of heterocellular communication. Role of Gap junctions and phospholipase A2. Circ Res. 1999;84:53-63.
75. You J, Marrelli SP, Bryan RM Jr. Role of cytoplasmic phospholipase A2 in endothelium-derived hyperpolarizing factor dilations of rat middle cerebral arteries. J Cereb Blood Flow Metab. 2002;22:1239-1247.
76. Adeagbo AS, Henzel MK. Calcium-dependent phospholipase A2 mediates the production of endothelium-derived hyperpolarizing factor in perfused rat mesenteric prearteriolar bed. J Vasc Res. 1998;35:27-35.
77. Fulton D, McGiff JC, Quilley J. Role of phospholipase C and phospholipase A2 in the nitric oxide-independent vasodilator effect of bradykinin in the rat perfused heart. J Pharmacol Exp Ther. 1996;278:518-526.
78. Edwards G, Dora KA, Gardener MJ, et al. K + is an endothelium-derived hyperpolarizing factor in rat arteries. Nature. 1998;396:269-272.
79. Sandow SL, Hill CE. Incidence of myoendothelial gap junctions in the proximal and distal mesenteric arteries of the rat is suggestive of a role in endothelium-derived hyperpolarizing factor-mediated responses. Circ Res. 2000;86:341-346.
80. Emerson GG, Segal SS. Electrical activation of endothelium evokes vasodilation and hyperpolarization along hamster feed arteries. Am J Physiol Heart Circ Physiol. 2001;280:H160-H167.
81. Chaytor AT, Martin PE, Edwards DH, et al. Gap junctional communication underpins EDHF-type relaxations evoked by ACh in the rat hepatic artery. Am J Physiol Heart Circ Physiol. 2001;280:H2441-H2450.
82. Miura H, Bosnjak JJ, Ning G, et al. Role for hydrogen peroxide in flow-induced dilation of human coronary arterioles. Circ Res. 2003;92:e31-e40.
83. Matoba T, Shimokawa H, Kubota H, et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in human mesenteric arteries. Biochem Biophys Res Commun. 2002;290:909-913.
84. Matoba T, Shimokawa H, Nakashima M, et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest. 2000;106:1521-1530.
85. Matoba T, Shimokawa H, Morikawa K, et al. Electron spin resonance detection of hydrogen peroxide as an endothelium-derived hyperpolarizing factor in porcine coronary microvessels. Arterioscler Thromb Vasc Biol. 2003;23:1224-1230.
86. Lacza Z, Puskar M, Kis B, et al. Hydrogen peroxide acts as an EDHF in the piglet pial vasculature in response to bradykinin. Am J Physiol Heart Circ Physiol. 2002;283:H406-H411.
87. You J, Johnson TD, Marrelli SP, et al. Functional heterogeneity of endothelial P2 purinoceptors in the cerebrovascular tree of the rat. Am J Physiol. 1999;277:H893-H900.
88. Tomioka H, Hattori Y, Fukao M, et al. Relaxation in different-sized rat blood vessels mediated by endothelium-derived hyperpolarizing factor: importance of processes mediating precontractions. J Vasc Res. 1999;36:311-320.
89. Urakami-Harasawa L, Shimokawa H, Nakashima M, et al. Importance of endothelium-derived hyperpolarizing factor in human arteries. J Clin Invest. 1997;100:2793-2799.
90. Shimokawa H, Yasutake H, Fujii K, et al. The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. J Cardiovasc Pharmacol. 1996;28:703-711.
91. Berman RS, Martin PE, Evans WH, et al. Relative contributions of NO and gap junctional communication to endothelium-dependent relaxations of rabbit resistance arteries vary with vessel size. Microvasc Res. 2002;63:115-128.
92. Barriere E, Tazi KA, Rona JP, et al. Evidence for an endothelium-derived hyperpolarizing factor in the superior mesenteric artery from rats with cirrhosis. Hepatology. 2000;32:935-941.
93. Chu CJ, Lee FY, Chang FY, et al. Hyperdynamic circulation in prehepatic portal hypertension: role of tumor necrosis factor-alpha. Zhonghua Yi Xue Za Zhi (Taipei). 1997;59:145-150.
94. Lopez-Talavera JC, Cadelina G, Olchowski J, et al. Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology. 1996;23:1616-1621.
95. Kilbourn RG, Belloni P. Endothelial cell production of nitrogen oxides in response to interferon gamma in combination with tumor necrosis factor, interleukin-1, or endotoxin. J Natl Cancer Inst. 1990;82:772-776.
96. Lopez-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology. 1995;108:761-767.
97. Katusic ZS, Stelter A, Milstien S. Cytokines stimulate GTP cyclohydrolase I gene expression in cultured human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol. 1998;18:27-32.
98. Rosenkranz-Weiss P, Sessa WC, Milstien S, et al. Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells. Elevations in tetrahydrobiopterin levels enhance endothelial nitric oxide synthase specific activity. J Clin Invest. 1994;93:2236-2243.
99. Wever RM, van Dam T, van Rijn HJ, et al. Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase. Biochem Biophys Res Commun. 1997;237:340-344.
100. Sztrymf B, Rabiller A, Nunes H, et al. Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats. Eur Respir J. 2004;23:752-758.
101. Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 1993;192:553-560.
102. Kitamura K, Sakata J, Kangawa K, et al. Cloning and characterization of cDNA encoding a precursor for human adrenomedullin. Biochem Biophys Res Commun. 1993;194:720-725.
103. Nuki C, Kawasaki H, Kitamura K, et al. Vasodilator effect of adrenomedullin and calcitonin gene-related peptide receptors in rat mesenteric vascular beds. Biochem Biophys Res Commun. 1993;196:245-251.
104. Fernandez-Rodriguez CM, Prada IR, Prieto J, et al. Circulating adrenomedullin in cirrhosis: relationship to hyperdynamic circulation. J Hepatol. 1998;29:250-256.
105. Genesca J, Gonzalez A, Catalan R, et al. Adrenomedullin, a vasodilator peptide implicated in hemodynamic alterations of liver cirrhosis: relationship to nitric oxide. Dig Dis Sci. 1999;44:372-376.
106. Wang P, Ba ZF, Cioffi WG, et al. The pivotal role of adrenomedullin in producing hyperdynamic circulation during the early stage of sepsis. Arch Surg. 1998;133:1298-1304.
107. Kojima H, Sakurai S, Uemura M, et al. Adrenomedullin contributes to vascular hyporeactivity in cirrhotic rats with ascites via a release of nitric oxide. Scand J Gastroenterol. 2004;39:686-693.
108. Nishimatsu H, Suzuki E, Nagata D, et al. Adrenomedullin induces endothelium-dependent vasorelaxation via the phosphatidylinositol 3-kinase/Akt-dependent pathway in rat aorta. Circ Res. 2001;89:63-70.